Clinical trials: Clopidogrel, completed
Adverse Drug Events, Adverse Drug Reactions
YouScript IMPACT Registry
This multicenter observational study aims to investigate the benefits of providing pharmacogenetic testing with the YouScript Personalized Prescribing System which includes a clinical decision support tool and individualized…
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- IMPACT (NCT02191358)
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Genelex Corporation
Healthy
Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects
Primary objective: Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with omeprazole 80 mg/day compared to…
- Trial name
- NCT01129375
- Testing
- clopidogrel, omeprazole
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Percutaneous Coronary Intervention
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI.
- Trial name
- INNOVATE-PCI (NCT00751231)
- Testing
- clopidogrel, PRT060128
- Where
- 59 sites in United States, Austria and 3 more
- Volunteers
- 652 people
- Sponsor
- Portola Pharmaceuticals
Coronary Disease
Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)
This study aims to demonstrate non-inferiority of Pidogrel ® compared to Plavix ® in patients with coronary disease: Primary Outcome Measures: measure of platelet reactivity by VerifyNow assay after 600 mg loading dose or after…
- Trial name
- (CAPP) (NCT01431495)
- Testing
- Pidogrel, Plavix
- Where
- Tunisia
- Volunteers
- 219 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Acute Coronary Syndromes
PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
The investigators hypothesize that reduced loading dose of prasugrel followed by reduced maintenance dose of prasugrel in acute coronary syndrome patients with CYP2C19 polymorphism undergoing percutaneous coronary intervention…
- Trial name
- PRAISE-GENE (NCT01641510)
- Testing
- Prasugrel, Clopidogrel
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Dong-A University
Coronary Artery Disease
Impact of Hybrid Coronary Revascularization on Antiplatelet Therapy
The effect of antiplatelet therapy is impaired among patients, who recently underwent on-pump coronary artery bypass grafting. The impact of hybrid coronary revascularization using minimal invasive surgical techniques on the…
- Trial name
- NCT02293928
- Testing
- Hybrid coronary revascularization
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Aarhus University Hospital Skejby
Chronic Total Occlusion of Coronary Artery, Vascular Disease
XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-AV DAPT (NCT01106534)
- Testing
- clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
- Where
- 144 sites in United States
- Volunteers
- 870 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Early stent thrombosis has been noted with increased frequency in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) who are treated with bivalirudin and clopidogrel.
- Trial name
- NCT01789814
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Tufts Medical Center
Coronary Artery Disease
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
The recommended antiplatelet treatment regimen for patients affected by acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) consists in the combination of aspirin and a P2Y12 receptor…
- Trial name
- SWAP-4 (NCT02287909)
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Florida
Healthy
Drug Interaction Study of Clopidogrel and Rosuvastatin
The purpose of this study is to determine if clopidogrel inhibits hepatic uptake transport of rosuvastatin clinically.
- Trial name
- NCT01469416
- Testing
- Rosuvastatin, Clopidogrel
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Coronary Artery Disease
Nobori Dual Antiplatelet Therapy as Appropriate Duration
NIPPON trial is a prospective, randomized, trial comparing 6 and 18 months Dual Antiplatelet Therapy (DAPT) following Nobori stent deployment.
- Trial name
- NCT01514227
- Testing
- Aspirin or thienopyridine, Aspirin and thienopyridine
- Where
- Japan
- Volunteers
- 3,773 people
- Sponsor
- Associations for Establishment of Evidence in Interventions
Symptomatic Aortic Stenosis
Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation
The narrowing of the aortic valve, which prevents blood from reaching the entire body correctly is a common disease in our environment.
- Trial name
- REACTIC-TAVI (NCT04331145)
- Testing
- Ticagrelor 60mg
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Andres Iñiguez Romo
Minor Stroke
Thrombolysis of Urokinase for Minor Stroke
This trial will enroll patients that have been diagnosed with minor stroke, which has occurred within the past 6 hours. TRUST is a prospective multicenter, randomized, blinded-endpoint study to evaluate the efficacy and safety of…
- Trial name
- TRUST (NCT04420351)
- Testing
- Urokinase thrombolysis, Aspirin;Clopidogrel
- Where
- China
- Volunteers
- 1,005 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Acute Coronary Syndrome, Angina, Unstable
Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
Patients with troponin-negative acute coronary syndrome (ACS) are not routinely pre-treated with P2Y12 inhibitors and the rate of high on-treatment platelet reactivity (HPR) remains elevated after a loading dose of ticagrelor at…
- Trial name
- NCT02925923
- Testing
- Ticagrelor, Eptifibatide, Clopidogrel
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Acute Coronary Syndrome, Coronary Artery Disease
Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention
Plavix (clopidogrel) is a drug that is approved by the FDA (Food and Drug Administration) to reduce the risk of having another heart attack by preventing platelets (blood cells that are important in forming blood clots) from…
- Trial name
- NCT01796873
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Arizona
Acute Coronary Syndrome
Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent
Background: The optimal duration of dual antiplatelet therapy in ACS patients treated with DES is still under debate. This is especially true for STEMI patients in the era of new anticoagulants and antiplatelet agents.
- Trial name
- REDUCE (NCT02118870)
- Testing
- Treatment 90 days DAPT, Treatment 360 days DAPT
- Volunteers
- 1,500 people
- Sponsor
- Diagram B.V.
Coronary Artery Disease
PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM PK (NCT01510327)
- Testing
- PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
- Where
- 5 sites in United States, Japan
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Polymorphisms of the cytochrome P450 (CYP) 2C19 enzyme has been consistently shown to modulate clopidogrel response. Accordingly, the Food and Drug Administration (FDA) has issued a warning on the potential for reduced efficacy…
- Trial name
- NCT03489863
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Florida
Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly
A randomized controlled, open label, multicenter trial with 1000 patients aged 70 years and older, presenting with Non-ST-elevation acute coronary syndrome.
- Conditions
- Non-ST-elevation Acute Coronary Syndrome, Unstable Angina, Non-ST-elevation Myocardial Infarction
- Trial name
- POPular AGE (NCT02317198)
- Testing
- Clopidogrel, Ticagrelor or Prasugrel
- Where
- Netherlands
- Volunteers
- 1,011 people
- Sponsor
- St. Antonius Hospital
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM LL (NCT01500434)
- Testing
- PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
- Where
- 30 sites in United States, Australia and 5 more
- Volunteers
- 102 people
- Sponsor
- Boston Scientific Corporation